Edgewise Therapeutics (EWTX) Competitors $25.67 +0.39 (+1.54%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$26.44 +0.77 (+3.00%) As of 03/14/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EWTX vs. SRPT, PCVX, ASND, QGEN, ROIV, LNTH, RVMD, BBIO, AXSM, and TLXShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Sarepta Therapeutics Vaxcyte Ascendis Pharma A/S Qiagen Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Sarepta Therapeutics (NASDAQ:SRPT) and Edgewise Therapeutics (NASDAQ:EWTX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations. Is SRPT or EWTX more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Edgewise Therapeutics' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Edgewise Therapeutics N/A -26.83%-25.67% Do analysts recommend SRPT or EWTX? Sarepta Therapeutics presently has a consensus target price of $170.41, suggesting a potential upside of 75.34%. Edgewise Therapeutics has a consensus target price of $45.38, suggesting a potential upside of 76.76%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 1 Sell rating(s) 3 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83Edgewise Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Do institutionals and insiders believe in SRPT or EWTX? 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 24.1% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, SRPT or EWTX? Edgewise Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B4.96-$535.98M$2.2842.63Edgewise TherapeuticsN/AN/A-$100.16M-$1.45-17.70 Does the media prefer SRPT or EWTX? In the previous week, Sarepta Therapeutics had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 16 mentions for Sarepta Therapeutics and 10 mentions for Edgewise Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.89 beat Edgewise Therapeutics' score of 0.24 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor SRPT or EWTX? Sarepta Therapeutics received 1430 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 75.18% of users gave Sarepta Therapeutics an outperform vote while only 73.47% of users gave Edgewise Therapeutics an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes146675.18% Underperform Votes48424.82% Edgewise TherapeuticsOutperform Votes3673.47% Underperform Votes1326.53% Which has more volatility & risk, SRPT or EWTX? Sarepta Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. SummarySarepta Therapeutics beats Edgewise Therapeutics on 14 of the 18 factors compared between the two stocks. Remove Ads Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.44B$7.03B$5.68B$8.13BDividend YieldN/A2.75%4.40%4.09%P/E Ratio-17.116.2923.8619.05Price / SalesN/A232.44395.1488.18Price / CashN/A65.6738.0534.64Price / Book5.676.596.834.29Net Income-$100.16M$142.18M$3.19B$247.48M7 Day Performance-8.35%-1.29%6.57%-0.85%1 Month Performance1.10%-8.97%-0.35%-9.36%1 Year Performance51.71%-6.24%11.96%4.02% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics1.7065 of 5 stars$25.67+1.5%$45.38+76.8%+50.4%$2.44BN/A-17.1160Positive NewsSRPTSarepta Therapeutics4.7708 of 5 stars$101.22-5.2%$173.52+71.4%-21.5%$9.67B$1.90B80.981,314Insider TradePCVXVaxcyte2.3675 of 5 stars$72.10-1.3%$147.50+104.6%+7.3%$9.28BN/A-15.67160Analyst ForecastPositive NewsASNDAscendis Pharma A/S3.0863 of 5 stars$151.93-3.0%$202.36+33.2%+2.1%$9.22B$363.64M-21.401,017Positive NewsQGENQiagen3.8885 of 5 stars$38.21-0.5%$47.71+24.9%-7.7%$8.48B$1.98B106.405,967Short Interest ↓ROIVRoivant Sciences2.0388 of 5 stars$10.17-5.3%$18.08+77.8%+4.2%$7.26B$122.59M-67.80860LNTHLantheus4.6654 of 5 stars$94.86+1.1%$132.86+40.1%+69.0%$6.60B$1.53B15.78700Short Interest ↓Positive NewsRVMDRevolution Medicines4.2091 of 5 stars$38.34-5.9%$66.31+72.9%+22.3%$6.45B$742,000.00-10.68250BBIOBridgeBio Pharma4.4351 of 5 stars$33.01-5.4%$51.67+56.5%+20.5%$6.28B$221.90M-11.58400AXSMAxsome Therapeutics4.7427 of 5 stars$127.15-0.3%$167.36+31.6%+74.8%$6.20B$385.69M-21.23380Analyst RevisionPositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.05+0.4%$22.00+21.9%N/A$6.08B$783.21M0.00N/AAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Sarepta Therapeutics Competitors Vaxcyte Competitors Ascendis Pharma A/S Competitors Qiagen Competitors Roivant Sciences Competitors Lantheus Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
